Content Inside :
Overview of TB Drug Issues
* Since streptomycin became available in 1948 drugs have become the mainstay of TB control
* But low cure rates occur because of poor access or compliance
* Leading to the emergence of Multiple drug resistant Tuberculosis (MDRTB)
Literature Review
* Standard text on Managing Drug Supply (yellow bible) not specific to TB
* Chaulet (1992) wrote key paper on TB drug issues. Highlighted additional costs (47-95% from taxes and duties)
* Weil (1994) surveyed TB drug availability in 74 countries. Identified difficulties
* Laing (1994) commented on stable international prices while US prices increased
Fixed Dose Combinations (FDC’s)
* WHO and IUATLD now recommend FDC’s for treatment of all new cases of TB
Justification
* Simplicity of treatment
* Improved compliance
* Logistic ease
* Prevent MDR
“FDC s will facilitate and support DOTS programs. They are not an alternative!”
My be you need full description for PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices, you can download this PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices or online view this PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices document. This PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices powerpoint presentation available from category Drugs. Download Seminar Paper Powerpoint Presentation PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices PPT slide and get information about PPT : Tuberculosis Drug Issues: Fixed Dose Combination Products Second Line Drugs, and Prices.
Category : Drugs